• Sensei Biotherapeutics, Inc. will present at two conferences in September 2024.
• Wainwright 26th Annual Global Investment Conference.
• The second conference is the Virtual and New York, NY 2024 Cantor Fitzgerald Global Healthcare Conference.
• The third conference is the Fireside Chat on Wednesday, September 18, 2024.
• Webcasts of both presentations will be available on the Investors section of the Sense.
BOSTON, Sept. 04, 2024 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, today announced that Company management will present at the following conferences in September 2024:
H.C. Wainwright 26th Annual Global Investment Conference
Corporate Presentation
Monday, September 9, 2024, at 7:00 a.m. ET.
Virtual and New York, NY
2024 Cantor Fitzgerald Global Healthcare Conference
Fireside Chat
Wednesday, September 18, 2024, at 2:30 p.m. ET.
New York, NY
Webcasts of both presentations will be available on the Investors section of the Sensei website. Replays will be on the website for approximately 90 days following the events.
About Sensei Biotherapeutics
Sensei Biotherapeutics (Nasdaq: SNSE) is a clinical stage immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients. Through its TMAb™ (Tumor Microenvironment Activated biologics) platform, Sensei develops conditionally active therapeutics designed to disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment. Sensei’s lead investigational candidate is SNS-101, a conditionally active antibody designed to block the V-domain Ig suppressor of T cell activation (VISTA) checkpoint selectively within the low pH tumor microenvironment, where VISTA acts as a suppressor of T cells by binding the receptor PSGL-1. The company is also developing SNS-102, a conditionally active monoclonal antibody targeting V-Set and Immunoglobulin Domain Containing 4 (VSIG-4); SNS-103, a conditionally active monoclonal antibody targeting ecto-nucleoside triphosphate diphosphohydrolase-1 (ENTPDase1), also known as CD39; and SNS-201, a conditionally active VISTAxCD28 bispecific antibody consisting of a CD28 agonist arm and a pH-sensitive anti-VISTA arm. For more information, please visit www.senseibio.com, and follow the company on X @SenseiBio and LinkedIn.
Investor Contact:
Michael Biega
Senior Director, Investor Relations
Sensei Biotherapeutics
This email address is being protected from spambots. You need JavaScript enabled to view it.
Media Contact:
Joyce Allaire
LifeSci Advisors
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$0.56 |
Daily Change: | -0.0005 -0.09 |
Daily Volume: | 83,398 |
Market Cap: | US$13.970M |
September 04, 2024 August 06, 2024 May 23, 2024 May 09, 2024 April 24, 2024 |
ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MOREImmix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB